Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AAM Calls For FTC Scrutiny Of Pharmacy Benefit Manager Practices

PBMs Often Fail To Encourage Generic And Biosimilar Use

Executive Summary

Pharmacy benefit managers often fail to encourage the use of generic and biosimilar medications and in fact undermine patient access to these more affordable drugs, the Association for Accessible Medicines has told the US Federal Trade Commission.

You may also be interested in...



FTC Seeks Input On How PBM Rebating Practices Affect Drug ‘Affordability,’ Access

With formal study still stalled, the information collection will enable FTC to examine a ‘wide array’ of pharmacy benefit manager business practices impacting patients, payers and pharmacies.

Medicare Part D Patients Paying More For Generics

The latest AAM-sponsored study from Avalere Health has found that, for the third year in the row, an increasing percentage of generic drugs are being placed on higher-cost non-generic tiers, even as the overall price of generic drugs decreases.

Merger Enforcement: FTC And Justice Department Casting Wide Net In Considering Changes

Agencies seek public comment on how they can modernize merger guidelines to enforce antitrust laws. List of questions, including what types of evidence show that a merger could reduce competition, indicate pharma and other mergers will face greater scrutiny.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151909

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel